Ritlecitinib PK Study in Healthy Volunteers

Phase 1, randomised, open-label trial of ritlecitinib tosilate in alopecia areata, ulcerative colitis (UC), Crohn's disease and 2 more (6 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition at 48 hours and Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition at 48 hours. Started Feb 2024; status: completed.